Physician profile
Wilfredo Rivera
NPI 1023170388
$2,640.88
in general payments reported to CMS, 2019-2025
20 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $93.40 · 2021: $184 · 2022: $719 · 2023: $749 · 2024: $287 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455 · Long Term Medical Supply Or Device Loan: $83.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.06 |
| Long Term Medical Supply Or Device Loan | $83.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $863.49 | 2022-2025 | Corevalve Evolut R, Aurora Ev-Icd Mri Surescan |
| Abiomed | $464.73 | 2023-2025 | Impella |
| Abbott Laboratories | $431.27 | 2019-2023 | Dragonfly Opstar |
| Philips North America LLC | $149.98 | 2025 | Coronary Other |
| Pfizer INC. | $131.73 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $91.30 | 2022-2025 | |
| Baxter Healthcare | $83.42 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Kestra Medical Technology Services, INC. | $60.80 | 2024-2025 | Assure Wcd |
| Merz North America, INC. | $53.52 | 2022-2024 | Xeomin |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.48 | 2022-2025 | Lifevest |
| Amgen INC. | $47.51 | 2023-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $42.26 | 2021-2022 | |
| Scpharmaceuticals INC. | $39.46 | 2023-2024 | |
| Surgenex LLC | $22.29 | 2025 | Surmatrix, Pellograft, Renograft |
| Lexicon Pharmaceuticals, INC. | $19.80 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.43 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $17.89 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $17.85 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.75 | 2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $16.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfredo Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.